GlobeNewswire Inc.··Levi & Korsinsky, LlpAquestive Therapeutics Faces Securities Fraud Lawsuit After 37% Stock Plunge
Aquestive Therapeutics faces securities fraud lawsuit after 37% stock drop tied to undisclosed FDA deficiencies in Anaphylm NDA. Lead plaintiff recruitment deadline: May 4, 2026.
AQSTsecurities fraudclass action lawsuit